5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients

Blood

Volumn 103, Issue 8, 2004, Pages 3055-3057

  Takahashi, Harumi ^b   Ieiri, Ichiro ^b   Wilkinson, Grant R ^b   Mayo, Gail ^b   Kashima, Toshitaka ^b   Kimura, Sosuke ^b   Otsubo, Kenji ^b   Echizen, Hirotoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; ALLELE; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DNA DETERMINATION; DNA FLANKING REGION; ENANTIOMER; ENVIRONMENTAL FACTOR; ETHNIC GROUP; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; CAUCASIAN; COMPARATIVE STUDY; GENETICS; JAPAN; METABOLISM;

ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; JAPAN; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); WARFARIN;

EID: 1842526962     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2521     Document Type: Article

References (16)

1. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974;16:348-354.
2. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther. 2003;73:253-263.
3. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-59.
4. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at: http://www. imm.ki.se/CY Palleles/. Accessed January 29, 2004.
5. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 2003;3:202-214.
6. Shintani M, Ieiri I, Inoue K, et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther. 2001;70:175-182.
7. Takahashi H, Kashima T, Kimura S, et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B. 1997;701:71-80.
8. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 1998;63:519-528.
9. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 1998;8:365-373.
10. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Stroke. 2000;31:817-821.
11. Leung A-YH, Chow H-CH, Kwong YL, at al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood. 2001;98:2584-2597.
12. de Morais SMF, Schweiki H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun. 1993;194:194-201.
13. Ibeanu GC, Goldstein JA. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry. 1995;34:8028-8036.
14. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. Transcriptional regulation of CYP2C9 gene: role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem. 2002;277:209-217.
15. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003;1619:243-253.
16. Ferguson SS, Lecluyse EL, Negishi M, Goldstein JA. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol. 2002;62:737-746.